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a b s t r a c t
N-acyloxyalkylation of NH-acidic compounds can be a prodrug approach for e.g. tertiary or some N-
heterocyclic amines and secondary amides and have the potential to modify the properties of the parent
drug for speciﬁc uses, for example its physicochemical, pharmacokinetic or biopharmaceutical proper-
ties. Aripiprazole lauroxil was prepared as a model compound for such prodrugs and its bioconversion
was investigated both in vitro and in vivo. Theoretically, N-acyloxyalkyl derivates of NH-acid compounds
undergo a two-step bioconversion into the parent NH-acidic drug through an N-hydroxyalkyl inter-
mediate. However, to our knowledge no published studies have investigated the formation of an
intermediate in vivo. In the present study, it was demonstrated that the assumed N-hydroxymethyl
intermediate was readily observed both in vitro and in vivo. In vivo, the observed plasma concentration of
the intermediate was at the same level as the drug (aripiprazole). When prodrug intermediates are
formed, it is important to make a proper pharmacological, pharmacokinetic and toxicological evaluation
of the intermediates to ensure patient safety; however, several challenges were identiﬁed when testing
an N-acyloxyalkyl prodrug. These included the development of a suitable bioanalytical method, the
accurate prediction of prodrug bioconversion and thereby the related pharmacokinetics in humans and
the toxicological potential of the intermediate.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Prodrugs are compounds that undergo a biological transformation
prior to achieving their pharmacological effect and have been known
for more than 50 years [1]. According to this deﬁnition, prodrugs are
xenobiotics that are inactive per se, but are transformed into one or
more active metabolites [2–4]. Although there is no universal deﬁni-
tion of a prodrug, recent deﬁnitions also describe prodrugs as
bioreversible derivatives of active drug molecules that undergo enzy-
matic and/or chemical transformation in vivo to produce the pharma-
cological active compound, which can then exert the intended
pharmacological effect [5,6]. Ideally, the prodrug should be converted
to the active parent compound, followed by a subsequent rapid
elimination of the released promoiety [7]. Furthermore, it has been
suggested that prodrugs should either be inactive or much less potent
(1000-times) than the parent drug [8]. Different functional groups are
amenable to prodrug design, as recently reviewed [9]. In both drug
discovery and drug development, the design of prodrugs is an
established tool for improvement of the physicochemical, biopharma-
ceutical, and/or pharmacokinetic properties of pharmacologically
active compounds. Prodrugs have been applied in a number of
different situations to overcome various barriers to drug formulation
and delivery, including poor aqueous solubility [10,11], chemical or
metabolic instability [12], insufﬁcient absorption [13–15], local delivery
as nasal [16] and lymphatic transport [17]. In 2004, Stella estimated
that 5–7% of drugs worldwide could be classiﬁed as prodrugs [18] and
in 2009, 13 of the 100 top-selling pharmaceuticals were prodrugs [4],
including the statins, Mevacors and Zocors, which are cyclic prodrugs
that have to be metabolised to the acyclic form that acts as the active
compound [3].
Utilization of the prodrug approach may provide a life cycle
management option for established drugs and thus the application
of the concept is intriguing but also challenging. Despite similarity
to the established drug the prodrug must be considered as a new
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chemical entity and its development planned and conducted
accordingly. The speciﬁc challenges from both drug discovery
and development perspectives include (i) possible pharmacologi-
cal activity of the prodrug; (ii) mode of prodrug conversion; (iii)
rate and extent of conversion of prodrug to active moiety in
species used for the toxicological evaluation to ensure proper
calculation of safety margins for the clinical development and later
use; and (iv) no alteration of the disposition properties, metabolic
capacity for or towards the active moiety [19]. Using the prodrug
principle as a means of life cycle management is, therefore, not
simple from a scientiﬁc, a developmental or a regulatory point of
view and requires signiﬁcant cross-functional efforts to succeed.
However, if the beneﬁt is clinical signiﬁcant for the patient, it
could be a potential enabling approach, for example, for a deﬁned
route of administration.
Aripiprazole is approved as an effective treatment for various
psychiatric disorders [20–23]. The compound is marketed in
several dosage formulations, including tablets, orally disintegrat-
ing tablets, an oral solution, and as a suspension for once-monthly
intramuscular injection as a depot. Recently an N-acyloxymethyl
prodrug of aripiprazole (aripiprazole lauroxil) intended for intra-
muscular injection has been described [24]. Bioconversion of N-
acyloxyalkyl derivatives of NH-acidic compounds is thought to
proceed through a hydrolytical two step process as previously
investigated and thoroughly described by Hans Bundgaard and
coworkers e.g. [25–31], as illustrated for aripiprazole lauroxil in
Fig. 1. The rate of prodrug conversion of N-acyloxymethyl deriva-
tives of NH-acidic compounds is ﬁrstly determined by the rate of
enzymatic or non-enzymatic catalysed hydrolysis of the ester
bond into the corresponding carboxylic acid and N-hydroxyalkyl
moieties followed by a non-enzymatic spontaneous cleavage into
the parent drug molecule and an aldehyde, e.g. formaldehyde as in
the case of aripiprazole lauroxil. The later process is thought to be
solely dependent on pH and temperature as previously described
[25,30–32]. To the best of our knowledge, no information is
available on the conversion of N-acyloxyalkyl derivates of NH-
acidic compounds focusing on simultaneous quantiﬁcation of all
components and intermediates in the two step bioconversion, i.e.,
the prodrug, the N-hydroxyalkyl intermediate and the parent NH-
acidic compound, both in vitro and in vivo. Thus, in the present
study, we use aripiprazole lauroxil as a model compound for an N-
acyloxyakyl prodrug of an N-acidic compound (drug) to provide an
insight into the biological conversion of these compounds.
2. Materials and methods
2.1. Chemicals
Aripiprazole was obtained from Otsuka pharmaceutics (Tokyo,
Japan), while N-hydroxymethyl-aripiprazole and aripiprazole lauroxil
were synthesised as described below. Reagents and solvents for the
synthetic work were obtained from Sigma-Aldrich (St. Louis, MO, USA)
and used as received. Viscoleo, Ph. Eur Grade medium chain triglycer-
ide, C8/C10 (MCT) was purchased from Delios V (Illertissen, Germany),
lecithin (E80) for the intravenous emulsion was obtained from Lipoid
AG (Ludwigshafen, Germany) and glycerol from Sigma Aldrich (St.
Louis, MO, USA). Hypergrade acetonitrile from Merck (Darmstadt,
Germany) was used for the HPLC–MS/MS analysis, ethanol was from
De Danske Spritfabrikker (Aalborg, Denmark) and deuterated aripi-
prazole used as the internal standard in the bioanalysis was purchased
from Toronto Research Chemicals Inc. (Toronto, ON, Canada). Puriﬁed
water was obtained from a Millipore Milli-Q Ultrapure Water puriﬁca-
tion system (Billerica, MA, USA). All other chemicals were of analytical
grade or higher.
2.2. Chemical synthesis
Aripiprazole lauroxil was obtained by an alkylation of aripipra-
zole using sodium hydride and chloromethyl laurate [33] in a
mixture of N,N-dimethylformamide and tetrahydrofuran. After an
aqueous work-up followed by column chromatography, aripipra-
zole lauroxil was isolated in 60% yield (LC purity: 96%) with data
corresponding to that reported in literature [24].
To obtain N-hydroxymethyl aripiprazole, aripiprazole was alkylated
using sodium hydride and benzyl chloromethyl ether in a mixture of
N,N-dimethylformamide and tetrahydrofuran [34]. After an aqueous
work-up followed by column chromatography, the BOM-protected
aripiprazole was isolated in 41% yield as conﬁrmed by analytical data
(data not shown). The BOM-protected aripiprazole was then stirred in
methanol containing one equivalent HCl and Pearlman’s catalyst
under an atmosphere of hydrogen to remove the benzyl group. The
mixture was ﬁltered and concentrated to give N-hydroxymethyl
aripiprazole HCl in 495% yield (LC purity: 89%) with data correspond-
ing to that reported in the literature [24].
2.3. In vitro conversion in buffer
To follow the spontaneous conversion from N-hydroxymethyl
aripiprazole to aripiprazole, a stock solution in DMSO-d6 was
made so the reaction could be started by adding the stock solution
into a phosphate buffer, pH 7.4, which thereby contained 0.5% v/v
DMSO-d6. The ﬁnal concentration of N-hydroxymethyl aripipra-
zole in the buffer was 9 mM equal to the solubility of aripiprazole
in water [35]. The degradation was followed at both 25 1C and 37
1C by continuous measurements.
1H NMR spectra were measured at 600.163 MHz on a Bruker AV-
III-600 equipped with a 5 mm TCI CryoProbe. Referencing was done to
DMSO-d6 (2.51 ppm). Solvent suppression with excitation sculpting
[36] using a square 180 pulse of 4 ms was applied on aqueous
solutions. Acquisition time was 1.7 s and repetition delay was 3 s A
Lorentzian Line broadening of 1.0 Hz was applied before FT, and the
aromatic region was baseline corrected manually using a 4th degree
polynomial ﬁt before integration.
2.4. In vitro conversion in plasma
An in vitro experiment was conducted in triplicate by adding 30
mL 1 mM aripiprazole lauroxil dissolved in ethanol to 1.47 mL rat
plasma from female Sprague Dawley rats at 37 1C. The spiked
plasma was stored at 37 1C and 50 mL aliquots were taken at
0.5 and 1.0 h post-spike. The aliquots were immediately treated
with 200 mL cold acetonitrile containing 0.4% citric acid and stored
at 80 1C until analysed as described in Section 2.7.
2.5. Formulations for the in vivo study
An emulsion for intravenous administration containing each of the
three compounds (i.e., aripiprazole, N-hydroxymethyl-aripiprazole or
aripiprazole lauroxil) in equimolar concentrations equivalent to 1 mg
aripiprazole was produced. The emulsions consisted of compound,
20% w/w fractionated coconut oil, 1.2% w/w lecithin, 2% w/w glycerol
and q.s. water. The amount of each compound added was 1 mg
aripiprazole/mL, 1.2 mg N-hydroxymethyl-aripiprazole/mL or 1.87 mg
aripiprazole lauroxil/mL, i.e., equimolar. Each of the three compounds
was dissolved in the oil together with lecithin and gently heated to 50
1C with continuous stirring. Glycerol was added to the aqueous phase
as an isotonic agent and the aqueous phase was heated to 50 1C. The
two phases were mixed and homogenised to a pre-emulsion by rapid
stirring for 1 min. The pre-emulsion was placed on ice and the droplet
size was further reduced by means of a homogeniser equipped with a
standard microtip at a power output of 5 (Soniﬁer Cell Disruptor,
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Model B15, Branson, Pusan, Korea) for 10 min. The formulation was
then ﬁltered through a 0.45 mm sterile ﬁlter into a sterilised glass
bottle with a rubber membrane and a crimped lid.
2.6. In vivo study
The protocol used for the in vivo study in rats was approved by
the institutional animal ethics committee in accordance with
Danish law regulating experiments on animals and in compliance
with EC directive 2010/63/EU, and the NIH guidelines on animal
welfare. Female Sprague Dawley rats, weighing 248–276 g on the
day of administration, obtained from Charles River (Sulzfeld,
Germany) were used for the pharmacokinetic studies (n ¼ 6 per
group). The animals were acclimatised for a minimum of 5 days in
groups of 2 on wooden bedding (Tapvei, Kortteinen, Finland) in
plastic cages, 595  380  200 mm3, with a stainless steel lid
(Scanbur, Sollentuna, Sweden) in humidity- and temperature-
controlled ventilation cupboards (Scantainers, Scanbur Technol-
ogy, Karlslunde, Denmark), relative humidity 40–60%, temperature
20 7 1 1C, light from 6:00–18:00 h. The animals had free access to
a standard rodent diet (Altromin 1325, Brogaarden, Denmark) and
water ad libitum during the study.
The animals were randomly assigned to three groups (n ¼
6 per group) receiving either aripiprazole, N-hydroxymethyl-
aripiprazole or aripiprazole lauroxil molar equivalent to 5 mg
aripiprazole/kg. The animals were dosed by injection into the tail
vein with a submicron emulsion containing a molar concentration
equivalent to 1 mg aripiprazole/mL. Blood samples of 100 mL were
obtained from the lateral tail vein by individual vein puncture and
collected into potassium–EDTA tubes (Microvette 500 K3E, Saar-
stedt, Nümbrecht, Germany). Samples was taken at 5, 15, 30 min
and 1, 2, 4, 6, 8 and 24 h after administration. Plasma was
harvested immediately by 10 min of centrifugation at 4 1C,
2765g (Multifuge 1 SR, Heraeus, Hanau, Germany) and stored
at 80 1C until analysed. At the end of the experiment, the
animals were sacriﬁced.
2.7. Bioanalysis
EDTA plasma samples were processed by protein precipitation
of 50 mL plasma with 200 mL ice-cold 0.4% citric acid in acetonitrile
containing 15 ng/mL aripiprazole-d8. The samples were mixed for
10 min in a shaking apparatus followed by centrifugation at 5000g
for 10 min at 15 1C and 150 mL supernatant was transferred to a
2 mL deep well plate. Calibration standards and quality control
(QCs) were prepared by adding standard solution to blank plasma
and prepared similarly to the plasma samples. The analysis was
performed by HPLC–MS/MS using a Waters Acquity-Xevo TQ
system controlled by UNIFI. The separation was done on a Waters
Spherisorb Silica column (3 mm, 100  2.1 mm2) with a mobile
phase consisting of water/acetonitrile (25/75 v/v) containing 1%
formic acid, at a ﬂow rate of 0.8 mL/min and a column oven
temperature of 45 1C. A 3 mL sample was injected in partial loop
with needle overﬁll mode. The mass spectrometer was operated in
the positive electrospray mode with a desolvation temperature of
650 1C. The analytes were detected by multiple-reaction-monitor-
ing: aripiprazole lauroxil (660.39–460.16 m/z), N-hydroxymethyl
aripiprazole (478.17–448.16 m/z) and aripiprazole (476.15–285.09
m/z). The run time of the assay was 3.5 min with the peaks eluting
between 1.45 and 1.84 min. The assay showed linearity over the
concentration range of 2.00–1000 ng/mL.
2.8. Data and statistical analysis
Results obtained are presented as means and the standard error
of the mean (mean 7 SEM) unless otherwise stated. Pharmaco-
kinetic parameters were calculated by using Phoenix version
6.3.0.0395 (Pharsight Corporation, Mountain View, CA, USA). The
plasma concentration–time proﬁles of the three compounds after
intravenous dosing were ﬁtted to a two-compartment model. The
area under the curve (AUC) was determined using the linear
trapezoidal method and extrapolation of the last measured plasma
concentration to inﬁnity.
3. Results and discussion
It is possible to prepare stable N-acyloxyalkyl derivatives of, e.
g., tertiary or some N-heterocyclic amines and secondary amides,
which are susceptible to enzymatic hydrolysis by esterases, with
subsequent spontaneous decomposition, as demonstrated with
pilocarpine [37], theophylline [38], penicillin G [39] and various
carboxylic acid agents [40]. For aripiprazole a similar stable
derivatisation can be made at the lactam moiety, where the
conversion and the relative presence of the three components –
prodrug, intermediate and aripiprazole – in the bioconversion was
investigated in vitro and in vivo in the present work.
3.1. In vitro bioconversion in rat plasma
To investigate the rate of biological conversion, two experi-
ments were conducted using either N-hydroxymethyl aripiprazole
added into a phosphate buffer or aripiprazole lauroxil added to rat
plasma at 37 1C. Since initial studies have demonstrated that
aripiprazole quickly precipitates and N-hydroxymethyl aripopra-
zole is rapidly converted to aripiprazole, NMR was selected as it is
a continuous measurement for analysis of N-hydroxymethyl ari-
poprazole to aripiprazole conversion. Furthermore, only a single
point determination was conducted for the full process in order to
demonstrate the suggested conversion route. When N-hydroxy-
methyl aripiprazole (Fig. 2) was added to phosphate buffer, a rapid
conversion was observed, i.e., a conversion that should not be rate
Fig. 1. Schematic presentation of the bioconversion of aripiprazole lauroxil. *Indicates the proton investigated in the 1H NMR study.
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limiting in vivo. The shift of the proton on C8 was followed, see
Fig. 1 (C8 marked with *). When the hydroxymethyl group was
attached a shift at 6.75 ppm was observed, whereas the shift
changed to 6.40 ppm when the group was removed. At 25 1C the
apparent ﬁrst-order rate constant was 0.0044 min1 and the half-
life was approximately 35 min. At 37 1C, however, the conversion
was so fast that the rate constant could not be measured with
sufﬁcient precision. More than half of the N-hydroxymethyl
aripiprazole was converted within the ﬁrst 15 min at 37 1C.
Estimated pKa for 3,4-dihydro-2(1H)-quinolinone is 14.6 [41]. If
this value is assumed similar for the NH-acidic group in aripipra-
zole a half-life of 12.7 h should be anticipated based upon the
prediction suggested by Bundgaard and Johansen [28]. This varia-
tion may be a reﬂection of a different chemical space used to make
the correlation or that the estimated pKa value for 3,4-dihydro-2
(1H)-quinolinone may not be similar to the pKa value for aripi-
prazole. The predicting deﬁned by Bundgaard and Johansen [28] is
very sensitive to the pKa value, for compounds with a pKa on 12.4
a half-life of 15 min would be estimated.
When aripiprazole lauroxil was added to rat plasma, concen-
trations of the expected N-hydroxymethyl intermediate in the
two-step degradation described in Fig. 1 could be observed when
analysed after both 0.5 and 1 h at 37 1C (see Fig. 3). The in vitro
bioconversion from the N-acyloxyalkyl derivate to the parent
compound observed in the present study is in accordance with
previous in vitro bioconversion studies investigating N-acylox-
yalkyl derivates [31,42–45]. Moreira and coworkers [39] have
described the in vitro conversion of O-amidomethyl penicilloate,
Fig. 2. Partial 1H NMR spectrum after addition of N-hydroxymethyl aripiprazole to phosphate buffer, pH 7.4; (A) at 25 1C measured at (from the bottom) 0.5, 1.3, 2.3 and 4.3 h
and (B) at 37 1C measured at (from the bottom) 14, 35 and 65 min.
Fig. 3. Mass chromatograms obtained after addition of aripiprazole lauroxil to plasma from female Sprague Dawley rats at 37 1C sampled after (A) 0.5 h and (B) 1 h.
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through an intermediate, with the very slow formation of peni-
cillin G, whereas Buur et al. reported the conversion of N-
acyloxymethyl derivates of 5-ﬂuorouracil to occur within a similar
timeframe as in the present study [25]. This study demonstrates
that during the conversion of aripiprazole lauroxil to aripiprazole,
N-hydroxymethyl aripiprazole is present in signiﬁcant amounts,
despite being a very short-lived intermediate compound as
revealed from the experiment when N-hydroxymethyl aripipra-
zole was added to a buffer. This adds to the complexity of
developing aripiprazole lauroxil as a safe drug, but also N-
acyloxyalkyl derivates in general, since the pharmacology and
toxicology of the intermediates needs to be put into the overall
equation.
3.2. In vivo study
In vitro data has limitations and may not reﬂect what occurs in
the whole organism. The conversion rate may be slower or faster,
the concentrations different, etc., which is why it is not always
possible to follow the entire bioconversion in vivo. The three
compounds, aripiprazole, N-hydroxymethyl aripiprazole and ari-
piprazole lauroxil, were therefore dosed intravenously to three
different groups of rats. The plasma concentration time proﬁle
following administration of aripiprazole can be seen in Fig. 4A. The
proﬁle could be described by a bi-exponential equation:
Cpl ¼ 1464Ue2:77tþ1205Ue0:16t ð3Þ
where Cpl is the concentration of aripiprazole (nanomol) in
plasma and t is time (in hours). The AUC0-1 was 8176 7 2647
nmol h/L, clearance 1.37 7 0.61 L/h/kg and volume of distribution
8.16 7 0.75 L/kg giving a terminal plasma half-life of E4.2 h. This
is slightly longer than that previously reported following non-
compartmental evaluation after p.o. dosing in male Sprague
Dawley rats [46].
The plasma concentration-time proﬁle after injection of N-
hydroxymethyl aripiprazole into rats is presented in Fig. 4B
together with the concentration of aripiprazole measured during
the bioconversion of N-hydroxymethyl aripiprazole. The plasma
concentration curve had a similar proﬁle for both compounds. The
bioconversion from N-hydroxymethyl aripiprazole did not seem to
be rate limiting for the formation of aripiprazole. This supports the
ﬁndings of the in vitro study. Analysis of the emulsion just after
dosing showed formation of aripiprazole (i.e., the exact pharma-
cokinetic parameters for N-hydroxymethyl aripiprazole and aripi-
prazole) cannot be described by this experiment. This highlights
some of the scientiﬁc problems when investigating these biocon-
versions. The intention was to stabilise the compound through
incorporation into a dispersed system, but hydrolysis was still
observed. Developing methods and procedures for the evaluation
of these intermediates is thus difﬁcult and may in part explain the
lack of in vivo investigations of prodrug conversion in the litera-
ture. However, from a drug development and patient safety point
of view, it is a critical parameter to consider.
The plasma concentration–time proﬁle after the injection of
aripiprazole lauroxil into rats is shown in Fig. 4C, together with the
amounts of N-hydroxymethyl aripiprazole and aripiprazole
formed as a result of the bioconversion of the prodrug. No
degradation of aripiprazole lauroxil was observed in the formula-
tion, i.e., aripiprazole lauroxil was sufﬁciently stable to allow a
pharmacokinetic evaluation of the compound. The clearance for
aripiprazole lauroxil was 0.32 7 0.11 L/h/kg. Interestingly, all
three compounds were detected in the animals, demonstrating
that the suggested biological conversion scheme presented in
Fig. 1 is the bioconversion route found in vivo, and was in
accordance with the observations from the in vitro study and the
previous work by Moreira et al. [39]. The in vitro data indicated a
high bioconversion of aripiprazole lauroxil, thus, the concentration
of N-hydroxymethyl aripiprazole observed in the animals dosed
with aripiprazole lauroxil was surprisingly high.
Quantiﬁcation of the intermediate N-hydroxymethyl aripipra-
zole complicated the bioanalysis signiﬁcantly. In order to get a
reliable measurement of a prodrug and all the associated meta-
bolites, it was generally important to stabilise the plasma samples
to prevent ex vivo degradation, which could impact the pharma-
cokinetic calculations. The bioanalytical method used in the
present work involved acidiﬁcation and cooling to stabilise the
intermediate, but degradation was still observed in the quality
samples through the analytical sequence. The mean deviation of
the quality samples was 16% from the nominal value, i.e., the
amount of N-hydroxymethyl aripiprazole was slightly
Fig. 4. Semi-log plot of mean (7 SEM) plasma concentration versus time of
equimolar intravenous doses of (A) aripiprazole (▴), (B) N-hydroxymethyl
aripiprazole (’), and (C) aripiprazole lauroxil (), administered to female Sprague
Dawley rats (n ¼ 6). For B) and C) in which bioconversion occurs, the concentra-
tions of aripiprazole and N-hydroxymethyl aripiprazole are also shown.
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underestimated. For intermediates with such a short half-life this
is methodically a challenge in particular for the in vivo studies.
With the formation of intermediates such as N-hydroxymethyl
aripiprazole, yet another challenge arises – the toxicological
potential of the intermediate – but also the release of formalde-
hyde in the last conversion. Prodrugs must be designed with at
least two speciﬁc sources of toxicity in mind: (i) toxicity of the
metabolites formed from the promoiety and (ii) a reactive meta-
bolic intermediate generated during bioconversion. One of the
signiﬁcant challenges for ester and N-acyloxyalkyl prodrugs is the
accurate prediction of pharmacokinetics in humans, owing to
signiﬁcant differences in speciﬁc carboxylesterase activity across
species [47], as previously reported for the exploratory diester
prodrug of nalbuphine [48]. The bioconversion in humans can
therefore happen at a different rate, why close monitoring of all
the components in both the pharmacokinetic and toxicological
studies is important to ensure that the right dose is given to
humans and that sufﬁcient coverage of the metabolites is obtained
in the species included in the toxicological evaluation of a given
prodrug. The bioconversion inherent in the nature of a prodrug
raises unanticipated issues that are not present in other drugs. This
monitoring is therefore essential to the safe and effective admin-
istration of a prodrug. The present study illustrates the potential
challenges of developing N-acyloxyalkyl derivates as prodrugs,
given that the potential pharmacological and toxicological effects
of the intermediates should been sufﬁciently analysed and
documented.
4. Concluding remarks
In conclusion, the present study has demonstrated that the
bioconversion of aripiprazole lauroxil to aripiprazole involves the
formation of an intermediate, N-hydroxymethyl aripiprazole. All
three compounds were detected in signiﬁcant amounts both
in vitro and in vivo, which give an indication of the complexity
associated with the use of prodrugs that involve a two-step
bioconversion.
This study also highlights some of the scientiﬁc problems
investigating these bioconversions. Though the intention was to
stabilise the compound through incorporation into a disperse
system, the afﬁnity for water or the placement in the interface
between the two phases was still signiﬁcant enough for major
degradation in just 3 h. Developing methods and procedures for
evaluation of these intermediates is, hence, linked to difﬁculties
and is probably one of the reasons for the lack of in vivo
investigations of prodrug conversion presented in the literature.
Notwithstanding these methodological issues, it is important that
these intermediates are identiﬁed and characterised in order to
ensure that they do not result in any unanticipated complications.
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